Top section
Top section
◆ Have capital markets comprehended the heatwave? ◆ Which SSA issuers need to get it done this autumn ◆ Halcyon days for MTN, M&A and ECM bankers
Investors pay little heed to alarming worsening of climate
New $75m partnership to develop treatment for lymphoma was “catalyst for investors”
More articles
More articles
More articles
-
Shanghai Fudan-Zhangjian Bio-Pharmaceutical Co has become the first Hong Kong-listed company to announce that it wants to float on China’s hotly-anticipated technology board. -
China-based biotechnology firm Mabpharm is looking for the greenlight to list in Hong Kong, having filed a draft IPO prospectus with the city’s stock exchange.
-
The EU has got another piece of its Sustainable Finance Action Plan over its most important political hurdle. At 5.30am on Thursday, after an all night session that had started at 8pm, negotiators in Brussels reached a deal on the Sustainability Disclosure Regulation. The law goes further than originally planned: investors are guided to consider their impacts on the real world, as well as inward risks to their portfolios, and to conduct due diligence.
-
Solar glass manufacturer Xinyi Solar Holdings has raised HK$1.32bn ($168m) after selling a block of new shares in a top-up placement.
-
In his latest Clawback column, Philippe Espinasse takes a look at the Hong Kong stock exchange’s new three year plan and its desire to be a global listing hub.
-
Link Real Estate Investment Trust has pulled off a record-breaking equity-linked deal, issuing the first green convertible notes in Asia Pacific, according to a source close to the transaction.
Sub-sections
shared comment list
